StrandDx™- ASD Exposome Sequencing Diagnostic was developed based on technology developed by Dr. Manish Arora, Christine Austin and Paul Curtin of the Institute for Exposomic Research at Mount Sinai. The FDA Breakthrough Device designation aims to expedite the review of innovative technologies
Linus Biotechnology Inc., a leader in precision exposome sequencing, announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD).
The FDA Breakthrough Device designation aims to expedite the review of innovative technologies that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Diagnosing ASD can be difficult because there is no FDA-approved molecular biomarker, like a blood test, to identify the disorder. Current ASD diagnosis relies on behavioral observation and it is usually diagnosed at approximately 4 years of age by an experienced professional. However, many children receive a final diagnosis at a much later age and do not receive the benefits of early intervention.
Diagnosing ASD can be difficult because there is no FDA-approved molecular biomarker, like a blood test, to identify the disorder.
StrandDx™-ASD is based on novel molecular biomarkers developed using Linus Biotechnology’s proprietary exposome and biological response sequencing platform, utilizing a single strand of hair. According to the Breakthrough Device designation label, the intended use of StrandDx™-ASD will extend to patients from birth to 21 years, where the test will assess the likelihood of ASD in children from birth to 18 months old, and aid in diagnosis of ASD in patients aged 18 months to 21 years.
“As our first precision exposome diagnostic, StrandDx™-ASD is being developed to help guide patient care for ASD, a disorder that now affects 1 in 44 children in the U.S. Molecular biomarkers, like StrandDx™-ASD, are a major step forward in precision medicine for autism and illustrate the potential to deploy individualized early intervention,” said Manish Arora, PhD, BDS, MPH, Edith J. Baerwald Professor and Vice Chair of the Department of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai and co-founder and Chief Scientific Officer of the Company. “This designation is a major milestone for Linus Biotechnology Inc. We look forward to working closely with the FDA to prioritize development of StrandDx™-ASD and moving it forward toward commercialization,” added Dr. Arora.
“Molecular biomarkers, like StrandDx™-ASD, are a major step forward in precision medicine for autism and illustrate the potential to deploy individualized early intervention,”
Dr. Manish Arora
The Precision Exposome Sequencing Platform described is based on technology developed by Dr. Manish Arora, Christine Austin and Paul Curtin, and other faculty members at the Icahn School of Medicine at Mount Sinai and licensed to Linus Biotechnology Inc. Mount Sinai and Mount Sinai researchers, including Manish Arora, have a financial interest in Linus Biotechnology Inc.